Charles A. Rowland Jr., Director at Nabriva Therapeutics plc (NBRV), sold 8,496 shares at $0.18 ($2K) on 2022-08-01, disclosed to the SEC on 2022-08-03.
Open-market sale of $2k NBRV by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| VKTX | SELL | 2023-05-18 | $1.0M | — | Filing → |
| GBIO | BUY | 2022-09-20 | $83K | — | Filing → |
| GBIO | BUY | 2022-09-19 | $552K | — | Filing → |